November 11, 2010
Researchers Use Stem Cells To Create Autism Model
Using induced pluripotent stem cells from patients with Rett syndrome, scientists at the University of California, San Diego School of Medicine have created functional neurons that provide the first human cellular model for studying the development of autism spectrum disorder (ASD) and could be used as a tool for drug screening, diagnosis and personalized treatment.
The research, led by Alysson R. Muotri, PhD, assistant professor of pediatrics, will be published in the November 12 issue of the journal Cell.
Rett (RTT) syndrome is a neurological disorder in which affected newborns display normal development until six months to 1Ã½ years of age, "after which behavioral symptoms begin to emerge," Muotri said. "Progressively, motor functions become impaired. There may be hypotonia or low muscle tone, seizures, diminished social skills and other autistic behaviors."
RTT was the focus of the research because its genetic underpinnings are well-understood. The condition is caused by mutations to the X-linked gene encoding a protein called MeCP2. By knocking out or adding the relevant gene in animal models, researchers can create the damaging effects of RTT or rescue impaired cells.
The new research goes further. Muotri and colleagues at the Salk Institute for Biological Studies and Pennsylvania State University developed a culture system using induced pluripotent stem cells (iPSCs) derived from RTT patient's skin fibroblasts "“ cells that typically give rise to connective tissues. Instead, the human RTT-iPSCs were reprogrammed to generate functional neurons that, compared to normal control cells, featured fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects "“ all indications that the deleterious alterations to human RTT neurons begin early in development.
The scientists also exposed human RTT-iPSCs to insulin growth factor 1 or IGF1. In a mouse model with RTT syndrome, IGF1 has been shown to improve symptoms, suggesting the protein might have similar potential for treating RTT and other neurological disorders in people. Muotri said IGF1 appeared to rescue some RTT-iPSCs, reverting some neuronal defects, though exactly how IGF1 works remains unknown and requires further investigation.
"This suggests, however, that synaptic deficiencies in Rett syndrome, and likely other autism spectrum disorders, may not be permanent," Muotri said.
Muotri said creation of a human RTT cell culture provides a new and unexplored developmental window before disease onset and possibly a common model for future studies of ASDs.
Co-authors of the paper are Maria C.N. Marchetto, Diana Yu, Yangling Mu and Fred Gage of the Salk Institute for Biological Studies; Cassiano Carromeu and Allan Acab of the UCSD School of Medicine, Department of Pediatrics/Rady Children's Hospital, Department of Cellular and Molecular Medicine and Stem Cell Program; Gene Yeo at the UCSD School of Medicine, Department of Cellular and Molecular Medicine and Stem Cell Program; and Gong Chen at Pennsylvania State University, Department of Biology.
This work was supported by the Emerald Foundation Young Investigator Award, the National Institutes of Health through the NIH Director's New Innovator Award Program, the California Institute for Regenerative Medicine, The Lookout Fund and the Picower Foundation.
On the Net: